MEDIPOST, Inc. Expands U.S. Presence with Key Executive Appointments, advances toward Phase III clinical trial of CARTISTEM® in North America
MEDIPOST Expands U.S. Presence, Bringing Hope to Osteoarthritis Patients
Table of Contents
South Korean biotech giant MEDIPOST, Inc. is making meaningful strides in its mission to bring its groundbreaking stem cell therapy, CARTISTEM®, to the U.S.market. The company recently announced the appointment of five senior executives, bolstering its team with decades of expertise in biologics and cell & gene therapy. This strategic move comes as MEDIPOST gears up for a Phase III clinical trial of CARTISTEM® in North America, a crucial step towards making this innovative treatment available to millions suffering from osteoarthritis (OA).
CARTISTEM®, the world’s first regulatory-approved allogeneic human umbilical cord blood-derived mesenchymal stem cell product, has already made a significant impact in South Korea. Launched in 2012 for the treatment of knee OA, it boasts over 10 years of real-world clinical data and has been used in more than 30,000 patients.
MEDIPOST’s U.S. team is laser-focused on securing Investigational New Drug (IND) approval from the FDA, paving the way for a Phase III clinical trial and ultimately, a Biologics License application (BLA) for commercial launch in North America.
This expansion is further fueled by MEDIPOST’s recent manufacturing partnership with OmniaBio. The opening of OmniaBio’s state-of-the-art cell and gene therapy manufacturing facility in Ontario provides MEDIPOST with access to cutting-edge technology and expertise, ensuring the scalable production and distribution of CARTISTEM® to meet the needs of the U.S. market.
“Our new leadership team brings an unparalleled wealth of experience, perfectly aligned with our aspiring goals,” said Edward Ahn, CEO of MEDIPOST, Inc. “Combined with our track record of success, proven product, and strong partnerships, MEDIPOST is ready to embark on its North American journey and poised to transform the lives of patients suffering from osteoarthritis. We’re incredibly excited for what lies ahead.”
Leading the Charge:
MEDIPOST’s newly appointed executives bring a wealth of experience to the table:
Adrian Orr,Head of Clinical Development: With 25 years of experience in osteoarthritis and cartilage repair research,Adrian will lead CARTISTEM® through its crucial clinical trials,bringing it closer to U.S. patients.
Jagannadha Rao Kandula, Ph.D., Head of CMC: Dr. Kandula’s expertise in cell and gene therapy manufacturing will ensure the highest quality and scalability of CARTISTEM® production.* [Insert remaining executive names and brief descriptions of their expertise]
MEDIPOST’s commitment to bringing CARTISTEM® to the U.S. represents a beacon of hope for millions living with the debilitating effects of osteoarthritis. With its experienced team, proven product, and strategic partnerships, MEDIPOST is well-positioned to revolutionize OA treatment and improve the quality of life for countless Americans.
MEDIPOST Strengthens U.S. Leadership Team as CARTISTEM Advances Towards Phase III Trials
Hamilton, Ontario – December 2, 2024 – MEDIPOST, Inc., a leading biotechnology company specializing in umbilical cord-derived stem cell therapies, today announced the expansion of its U.S.leadership team with the appointment of four key executives. This strategic move comes as the company prepares to initiate a Phase III clinical trial for its flagship product, CARTISTEM, a groundbreaking allogeneic stem cell therapy for knee osteoarthritis (OA).
The newly appointed executives bring a wealth of experience in cell therapy development, manufacturing, and commercialization, further strengthening MEDIPOST’s position in the U.S. market.
The new leadership team members include:
dr.Srinivas Rao, Head of CMC (Chemistry, Manufacturing, and Controls): Dr. Rao boasts over 25 years of experience scaling protein biologics and cell therapies. Most recently, he served as Senior Director, Cell Therapy Manufacturing Sciences and Commercialization at Bristol Myers Squibb, where he played a pivotal role in the approval and commercialization of six biologics and two cell therapy products. Keith Bentlage, Head of project Management Office: With over 30 years of experience as a program architect, Keith has a proven track record of successfully leading programs to Phase III trial completion and commercial launch, consistently delivering on time and within budget. Richard Ong, Head of Quality: Richard brings extensive industry expertise gained at leading companies like Amgen, Shire, Merrimack, and Lonza. His deep understanding of quality’s impact on process development and manufacturing will be crucial as CARTISTEM progresses through commercialization. Richard is committed to maintaining the highest standards of excellence for the therapy.
Raymond Bergeron, Head of Accounting & Controller: Raymond brings over 20 years of financial leadership experience in the biotech and investment management sectors. his tenure at bluebird bio and Evelo Biosciences (founded by Flagship pioneering) has honed his skills in crafting efficient operational strategies and driving strategic growth.
“We are thrilled to welcome these exceptional leaders to the MEDIPOST team,” said [Name and Title of MEDIPOST CEO].”Their combined expertise and proven track records will be instrumental as we advance CARTISTEM through its next phase of clinical development and prepare for commercialization in the U.S. market.”
CARTISTEM, approved in Korea in 2012, has already treated over 30,000 patients for knee OA. Following a successful Phase 1/2a U.S. clinical trial, MEDIPOST is now preparing its Investigational New Drug (IND) application to begin a Phase III study.
In partnership with the Center for Commercialization of Regenerative Medicine (CCRM), MEDIPOST has established OmniaBio, a cell and gene therapy contract development and manufacturing organization (CDMO) based in Hamilton, Ontario. OmniaBio will play a key role in manufacturing CARTISTEM for the U.S. market.
About MEDIPOST, Inc.
MEDIPOST, Inc. is a leading commercial-stage biotechnology company dedicated to developing innovative umbilical cord-derived stem cell therapies for inflammation-driven degenerative diseases.
local Artist’s Upcycled Creations turn Trash into Treasure
[City, State] – Forget diamonds, [Artist Name] is turning trash into treasure. This local artist is making waves with their unique creations,transforming discarded materials into stunning works of art.
[Artist Name]’s studio, nestled in the heart of [Neighborhood], is a wonderland of salvaged objects. Rusted metal scraps, broken toys, and discarded fabric scraps find new life in their hands, becoming intricate sculptures, whimsical mobiles, and eye-catching jewelry.
“I’ve always been drawn to the beauty in the unexpected,” [Artist Name] says. “There’s a story in every discarded object, and I love giving those stories a second chance.”
[insert image of artist working on a piece or a finished piece here]
[Artist name]’s work has garnered attention not only for its artistic merit but also for its commitment to sustainability. In a world grappling with overflowing landfills, their art serves as a powerful reminder of the potential for reuse and repurposing.
“It’s about more than just creating art,” [Artist Name] explains.”It’s about challenging our relationship with consumption and showing that beauty can be found in the most unexpected places.”
[Artist Name]’s creations are currently on display at [Gallery Name] in [City]. The exhibition, titled ”[Exhibition Name],” runs until [Date].
For those looking to add a touch of unique,eco-conscious art to their homes,[Artist Name] also accepts commissions.
MEDIPOST Expands Footprint, Bringing Hope Closer for OA Patients
Hamilton, ON (December 2, 2024) – Today, newsdirectory3.com speaks with Dr. [Insert name adn title], a leading stem cell expert, regarding groundbreaking developments from South Korean biotechnology company MEDIPOST, Inc. MEDIPOST’s presence is expanding rapidly in teh United States, with the goal of bringing their innovative stem cell therapy, CARTISTEM®, to american patients suffering from osteoarthritis.
ND3: Dr. [Expert Name], MEDIPOST is generating considerable buzz in the medical community. Can you tell us about their work and what makes CARTISTEM® so unique?
Dr.[Expert name]: MEDIPOST has already made meaningful strides in South Korea with CARTISTEM®.It’s the world’s first regulatory-approved, allogeneic human umbilical cord blood-derived mestenchymal stem cell product, treating knee OA since 2012 with over 10 years of real-world data and triumphant use in more than 30,000 patients. This is remarkable and speaks to the therapy’s safety and efficacy.
ND3: What are the implications for American patients facing osteoarthritis, a condition affecting millions?
Dr. [Expert Name]: Osteoarthritis can be debilitating, often limiting mobility and impacting quality of life. Current treatment options are frequently enough limited to pain management. CARTISTEM® offers the potential for a new approach, possibly slowing disease progression by leveraging the regenerative properties of stem cells.
ND3: MEDIPOST recently strengthened their U.S. team drastically. How significant is this for their progress towards making CARTISTEM® available in the U.S.?
Dr. [Expert Name]: Bringing a novel therapy to market is a complex process,requiring expertise in various areas. MEDIPOST’s appointments of seasoned executives with deep experience in fields like clinical advancement,manufacturing,and regulatory affairs is crucial. It demonstrates their commitment and preparedness to navigate the FDA approval process.
ND3: You mentioned the FDA approval process. What are the next steps for MEDIPOST in bringing CARTISTEM® to American patients?
Dr. [Expert Name]:
MEDIPOST is focused on securing Investigational New drug (IND) approval from the FDA, which will pave the way for a critical Phase III clinical trial in North America. If successful, this trial will provide the necessary data for a Biologics License Application (BLA), the final hurdle towards commercial availability in the U.S.
ND3: This sounds promising. What is your overall assessment of MEDIPOST’s potential impact in the field of osteoarthritis treatment?
Dr. [Expert Name]: MEDIPOST is at the forefront of stem cell therapy research.If successful, CARTISTEM® has the potential to revolutionize how we treat osteoarthritis, offering patients a new hope for long-term pain relief and improved quality of life. We’ll be watching MEDIPOST’s progress with grate interest.
ND3: Thank you for sharing your insights, Dr. [Expert Name].
this interview with Dr.[Expert Name] offers valuable insight into MEDIPOST’s ambitious goals and the potential impact of CARTISTEM® for millions of Americans struggling with osteoarthritis.
As MEDIPOST progresses through the regulatory process, newsdirect3.com will continue to track their advancements and bring you the latest updates on this potentially transformative therapy.